报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
---|---|---|---|---|---|---|---|---|
2024-06-30 | 30.71% | 128.61% | -1.22% | 115/158 | 32.75% | 艾力斯 | 95.8% | 行业排名> |
2024-03-31 | 31.09% | 530.82% | 7.22% | 115/158 | 51.26% | 百利天恒 | 97.99% | 行业排名> |
2023-12-31 | 29% | 55.84% | 46.45% | 122/158 | 51.17% | 百利天恒 | 98.92% | 行业排名> |
2023-09-30 | 19.8% | 100.73% | 47.39% | 139/158 | 32.69% | 迈威生物 | 98.93% | 行业排名> |
2023-06-30 | 13.43% | 1461.27% | 286.15% | 141/158 | 38.03% | 迈威生物 | 99.59% | 行业排名> |
2023-03-31 | -7.22% | 82.24% | -138.79% | 143/158 | 52.88% | 迈威生物 | 99.8% | 行业排名> |
2022-12-31 | 18.61% | 161.12% | 88.64% | 143/158 | 53.39% | 迈威生物 | 99.46% | 行业排名> |
2022-09-30 | 9.86% | 172.85% | 1099.49% | 138/158 | 6.36% | 迈威生物 | 99.75% | 行业排名> |
2022-06-30 | -0.99% | 95.63% | 97.57% | 145/158 | 21.22% | 迈威生物 | 99.67% | 行业排名> |
2022-03-31 | -40.64% | 26.78% | -33.51% | 135/158 | 54.47% | 迈威生物 | 99.44% | 行业排名> |
2021-12-31 | -30.44% | -265.26% | -124.83% | 148/158 | 54.96% | 迈威生物 | 98.57% | 行业排名> |
2021-09-30 | -13.54% | -972.26% | 40.08% | 132/158 | 46.94% | 首药控股 | 99.93% | 行业排名> |
2021-06-30 | -22.59% | 69.33% | 59.29% | 140/158 | 47.38% | 艾力斯 | 99.41% | 行业排名> |
2021-03-31 | -55.5% | 70.88% | -401.34% | 122/158 | 54.17% | 艾力斯 | 98.7% | 行业排名> |
2020-12-31 | 18.42% | 136.93% | 1086.71% | 139/158 | -145.98% | 艾力斯 | 99.4% | 行业排名> |
2020-09-30 | 1.55% | 2% | 102.11% | 118/158 | 56.57% | 首药控股 | 99.94% | 行业排名> |
2020-06-30 | -73.67% | 2% | -47.73% | 128/158 | 54.3% | 泽璟制药 | 99.96% | 行业排名> |
2019-12-31 | -49.87% | 90.54% | 73.83% | 135/158 | -1213.5% | 微芯生物 | 95.14% | 行业排名> |
2019-03-31 | -190.59% | 2% | 63.86% | 106/158 | 51.34% | 多瑞医药 | 95.59% | 行业排名> |
2018-12-31 | -527.32% | -656.91% | -656.91% | 132/158 | -207.91% | 微芯生物 | 95.81% | 行业排名> |
2015-12-31 | 94.69% | 30.12% | 30.12% | 2/158 | 46.24% | 微芯生物 | 96.09% | 行业排名> |
2014-12-31 | 72.77% | 2% | 2% | 11/158 | 43.42% | 微芯生物 | 96.11% | 行业排名> |